N Coburn1, R Cosby2, L Klein3, G Knight4, R Malthaner5, J Mamazza6, C D Mercer7, J Ringash8. 1. Odette Cancer Centre, Toronto. 2. Program in Evidence-Based Care, Department of Oncology, McMaster University, Hamilton. 3. Humber River Regional Hospital, Toronto. 4. Grand River Regional Cancer Centre, Kitchener. 5. London Regional Cancer Program, London. 6. Ottawa Civic Hospital, Ottawa. 7. Hotel Dieu Hospital, Kingston; and. 8. Princess Margaret Hospital, Toronto, ON.
Abstract
BACKGROUND: Resection is the cornerstone of cure for gastric adenocarcinoma; however, several aspects of surgical intervention remain controversial or are suboptimally applied at a population level, including staging, extent of lymphadenectomy (lnd), minimum number of lymph nodes that have to be assessed, gross resection margins, use of minimally invasive surgery, and relationship of surgical volumes with patient outcomes and resection in stage iv gastric cancer. METHODS: Literature searches were conducted in databases including medline (up to 10 June 2016), embase (up to week 24 of 2016), the Cochrane Library and various other practice guideline sites and guideline developer Web sites. A practice guideline was developed. RESULTS: One guideline, seven systematic reviews, and forty-eight primary studies were included in the evidence base for this guidance document. Seven recommendations are presented. CONCLUSIONS: All patients should be discussed at a multidisciplinary team meeting, and computed tomography (ct) imaging of chest and abdomen should always be performed when staging patients. Diagnostic laparoscopy is useful in the determination of M1 disease not visible on ct images. A D2 lnd is preferred for curative-intent resection of gastric cancer. At least 16 lymph nodes should be assessed for adequate staging of curative-resected gastric cancer. Gastric cancer surgery should aim to achieve an R0 resection margin. In the metastatic setting, surgery should be considered only for palliation of symptoms. Patients should be referred to higher-volume centres and those that have adequate support to manage potential complications. Laparoscopic resections should be performed to the same standards as those for open resections, by surgeons who are experienced in both advanced laparoscopic surgery and gastric cancer management.
BACKGROUND: Resection is the cornerstone of cure for gastric adenocarcinoma; however, several aspects of surgical intervention remain controversial or are suboptimally applied at a population level, including staging, extent of lymphadenectomy (lnd), minimum number of lymph nodes that have to be assessed, gross resection margins, use of minimally invasive surgery, and relationship of surgical volumes with patient outcomes and resection in stage iv gastric cancer. METHODS: Literature searches were conducted in databases including medline (up to 10 June 2016), embase (up to week 24 of 2016), the Cochrane Library and various other practice guideline sites and guideline developer Web sites. A practice guideline was developed. RESULTS: One guideline, seven systematic reviews, and forty-eight primary studies were included in the evidence base for this guidance document. Seven recommendations are presented. CONCLUSIONS: All patients should be discussed at a multidisciplinary team meeting, and computed tomography (ct) imaging of chest and abdomen should always be performed when staging patients. Diagnostic laparoscopy is useful in the determination of M1 disease not visible on ct images. A D2 lnd is preferred for curative-intent resection of gastric cancer. At least 16 lymph nodes should be assessed for adequate staging of curative-resected gastric cancer. Gastric cancer surgery should aim to achieve an R0 resection margin. In the metastatic setting, surgery should be considered only for palliation of symptoms. Patients should be referred to higher-volume centres and those that have adequate support to manage potential complications. Laparoscopic resections should be performed to the same standards as those for open resections, by surgeons who are experienced in both advanced laparoscopic surgery and gastric cancer management.
Authors: Melissa C Brouwers; Michelle E Kho; George P Browman; Jako S Burgers; Francoise Cluzeau; Gene Feder; Béatrice Fervers; Ian D Graham; Jeremy Grimshaw; Steven E Hanna; Peter Littlejohns; Julie Makarski; Louise Zitzelsberger Journal: CMAJ Date: 2010-07-05 Impact factor: 8.262
Authors: R J E Skipworth; R W Parks; N A Stephens; C Graham; D H Brewster; O J Garden; S Paterson-Brown Journal: Eur J Surg Oncol Date: 2009-10-30 Impact factor: 4.424
Authors: Sepideh Gholami; Lucas Janson; David J Worhunsky; Thuy B Tran; Malcolm Hart Squires; Linda X Jin; Gaya Spolverato; Konstantinos I Votanopoulos; Carl Schmidt; Sharon M Weber; Mark Bloomston; Clifford S Cho; Edward A Levine; Ryan C Fields; Timothy M Pawlik; Shishir K Maithel; Bradley Efron; Jeffrey A Norton; George A Poultsides Journal: J Am Coll Surg Date: 2015-05-05 Impact factor: 6.113
Authors: Jordan Levy; Vaibhav Gupta; Elmira Amirazodi; Catherine Allen-Ayodabo; Naheed Jivraj; Yunni Jeong; Laura E Davis; Alyson L Mahar; Charles De Mestral; Olli Saarela; Natalie Coburn Journal: Gastric Cancer Date: 2019-11-04 Impact factor: 7.370
Authors: Piotr Małczak; Grzegorz Torbicz; Mateusz Rubinkiewicz; Natalia Gajewska; Nadia Sajuk; Kamil Rozmus; Michał Wysocki; Piotr Major; Andrzej Budzyński; Michał Pędziwiatr Journal: Cancer Manag Res Date: 2018-12-06 Impact factor: 3.989
Authors: Sofie De Vuysere; Vincent Vandecaveye; Yves De Bruecker; Saskia Carton; Koen Vermeiren; Tim Tollens; Frederik De Keyzer; Raphaëla Carmen Dresen Journal: BMC Med Imaging Date: 2021-02-05 Impact factor: 1.930
Authors: Afsaneh Barzi; Lisa M Hess; Yajun E Zhu; Astra M Liepa; Tomoko Sugihara; Julie Beyrer; Joseph Chao Journal: Cancer Control Date: 2019 Jan-Dec Impact factor: 3.302